Dr. Penny Glickman, MD (she/her) is an Endocrinologist in Maitland, FL with over 17 years of experience. What is your opinion of Dr. Penny Glickman, MD? Rate this provider below so other people can make informed decision.
Over 17 Years of Experience
Many providers receive payments from medical companies such as pharmaceutical companies and medical device companies. These payments can range from small amounts for meals to large consulting fees. We provide this information in order to make healthcare system more transparent. Between 2014 and 2020 Dr. Penny Glickman, MD has received over $77,207 which includes payments from the following companies:
$31,750.18 from Boehringer Ingelheim Pharmaceuticals, Inc.
$16,656.91 from Tandem Diabetes Care, Inc.
$10,691.79 from LILLY USA, LLC
$6,548.54 from AstraZeneca Pharmaceuticals LP
$1,948.17 from sanofi-aventis U.S. LLC
$1,004.55 from INSULET CORPORATION
$997.14 from Novo Nordisk Inc
$814.55 from Amgen Inc.
$785.69 from AbbVie, Inc.
$704.20 from Merck Sharp & Dohme Corporation
$597.97 from Dexcom, Inc.
$524.60 from Janssen Pharmaceuticals, Inc
$382.05 from Abbott Laboratories
$301.35 from Amarin Pharma Inc.
$298.91 from GlaxoSmithKline, LLC.
$279.36 from Medtronic MiniMed, Inc.
$216.66 from Valeritas, Inc.
$209.19 from Kowa Pharmaceuticals America, Inc.
$195.11 from Shire North American Group Inc
$166.51 from Takeda Pharmaceuticals America, Inc.
Payments received by Dr. Penny Glickman, MD were from the following categories:
$48,350.00 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Do you have any questions about your diabetes condition or general questions about diabetes? You can now post those questions in DiabetesIQ Forum and have our diabetes experts answer your questions for FREE! Yes, there is absolutely no catch! - Registration only takes a few seconds and it's FREE. No credit card needed. You can ask any number of diabetes questions, all for FREE! Register today and join the conversation!